NASDAQ:DARE Dare Bioscience (DARE) Stock Price, News & Analysis $0.72 -0.02 (-2.08%) Closing price 10/16/2026 04:00 PM EasternExtended Trading$0.73 +0.01 (+0.75%) As of 10/16/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings About Dare Bioscience Stock (NASDAQ:DARE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Dare Bioscience alerts:Sign Up Key Stats Today's Range$0.71▼$0.7450-Day Range$0.71▼$1.4452-Week Range$0.69▼$3.78Volume77,209 shsAverage Volume215,204 shsMarket Capitalization$14.25 millionP/E RatioN/ADividend YieldN/APrice Target$6.50Consensus RatingHold Company Overview Daré Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies designed to address women’s health needs. Its research programs span contraception, vaginal and reproductive health, fertility, pregnancy and postpartum care, and menopause. The company’s lead commercial product, XACIATO (clindamycin phosphate) vaginal gel 2%, is an FDA-approved prescription treatment for bacterial vaginosis. Daré’s development pipeline has also included Ovaprene, a hormone-free monthly intravaginal contraceptive, and investigational candidates intended to address contraception, sexual health, vaginal conditions and hormone-related disorders. Daré Bioscience is headquartered in San Diego, California, and conducts development activities through collaborations with biotechnology, pharmaceutical and academic partners. The company’s programs are primarily directed toward the U.S. market while seeking opportunities for broader international development and commercialization. Sabrina Martucci Johnson serves as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Dare Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreDARE MarketRank™: 2.45211726384 of 5 starsDare Bioscience scored higher than 49% of companies evaluated by MarketBeat, and ranked 510th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingDare Bioscience has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialDare Bioscience has a consensus price target of $6.50, representing about 797.0% upside from its current price of $0.72.Amount of Analyst CoverageDare Bioscience has only been the subject of 3 research reports in the past 90 days.Read more about Dare Bioscience's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Dare Bioscience are expected to grow in the coming year, from ($0.69) to ($0.31) per share.Price to Book Value per Share RatioDare Bioscience has a P/B Ratio of 3.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Dare Bioscience's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.89% of the float of Dare Bioscience has been sold short.Short Interest Ratio / Days to CoverDare Bioscience has a short interest ratio ("days to cover") of 3.08, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Dare Bioscience has recently increased by 7.31%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDare Bioscience does not currently pay a dividend.Dividend GrowthDare Bioscience does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.62 News SentimentDare Bioscience has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Dare Bioscience this week, compared to 3 articles on an average week.MarketBeat Follows3 people have added Dare Bioscience to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dare Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders3.40% of the stock of Dare Bioscience is held by insiders.Percentage Held by Institutions6.70% of the stock of Dare Bioscience is held by institutions.Read more about Dare Bioscience's insider trading history. Receive DARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dare Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DARE Stock News HeadlinesDaré Bioscience Launches CEO Corner Series To Update Investors On Women's Health PipelineOctober 13, 2026 | rttnews.comDaré Bioscience Launches “CEO Corner” Video Series to Highlight the Company’s Pipeline of Women’s Health Innovations, Corporate Strategy and OpportunitiesOctober 13, 2026 | finance.yahoo.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now. | Stansberry Research (Ad)Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company's Pipeline of Women's Health Innovations, Corporate Strategy and OpportunitiesOctober 13, 2026 | globenewswire.comDaré Bioscience Highlights 187-Fold Lower Sildenafil Exposure In Phase 1 StudyOctober 8, 2026 | rttnews.comDaré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific MeetingOctober 8, 2026 | markets.businessinsider.comL’action Dare Bioscience en hausse après l’obtention d’un brevet pour le traitement du HPVSeptember 28, 2026 | fr.investing.comDaré Bioscience, Inc. Announces Dare-Hpv Phase 2 Study for Persistent High-Risk Hpv Infection UnderwaySeptember 28, 2026 | marketscreener.comMSee More Headlines DARE Stock Analysis - Frequently Asked Questions How have DARE shares performed this year? Dare Bioscience's stock was trading at $1.93 at the start of the year. Since then, DARE stock has decreased by 62.5% and is now trading at $0.7246. How were Dare Bioscience's earnings last quarter? Dare Bioscience, Inc. (NASDAQ:DARE) posted its earnings results on Thursday, August, 13th. The biotechnology company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.10. The biotechnology company had revenue of $0.19 million for the quarter, compared to analyst estimates of $0 million. Dare Bioscience had a negative trailing twelve-month return on equity of 748.30% and a negative net margin of 803.80%. Read the conference call transcript. When did Dare Bioscience's stock split? Dare Bioscience shares reverse split before market open on Monday, July 1st 2024.The 1-12 reverse split was announced on Monday, July 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. When did Dare Bioscience IPO? Dare Bioscience (DARE) raised $102 million in an IPO on Thursday, April 10th 2014. The company issued 8,500,000 shares at a price of $11.00-$13.00 per share. How do I buy shares of Dare Bioscience? Shares of DARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dare Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dare Bioscience investors own include Tonix Pharmaceuticals (TNXP), Tesla (TSLA), Bionano Genomics (BNGO), Gevo (GEVO), Ideanomics (IDEX), NIO (NIO) and Matinas Biopharma (MTNB). Company Calendar Last Earnings8/13/2026Today10/16/2026EGM 202611/10/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 DARE's financial health is in the Red zone, according to TradeSmith. DARE has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:DARE CIK1401914 Webwww.darebioscience.com Phone(858) 926-7655Fax617-494-1544Employees24Year Founded2006Price Target and Rating Average Price Target for Dare Bioscience$6.50 High Price Target$12.00 Low Price Target$1.00 Potential Upside/Downside+797.0%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.40 million Net Margins-803.80% Pretax Margin-803.80% Return on Equity-748.30% Return on Assets-38.75% Debt Debt-to-Equity RatioN/A Current Ratio0.99 Quick Ratio0.99 Sales & Book Value Annual Sales$1.03 million Price / Sales13.84 Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book3.62Miscellaneous Outstanding Shares19,670,000Free Float19,000,000Market Cap$14.25 million OptionableNot Optionable Beta1.01 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:DARE) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dare Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dare Bioscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
